While adenomas and benign tumors, as well as normal tissues, rarely express MAP17, a high proportion (50 to 90%) of late-stage or metastatic tumors show high levels of MAP17, correlating with a more de-differentiated phenotype [17, 22, 24–26]. The gene discussed is PDZK1IP1; the disease is benign neoplasm.